Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome - Authors' reply
- PMID: 37407140
- DOI: 10.1016/S2352-3026(23)00176-X
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome - Authors' reply
Conflict of interest statement
The HARMONY trial was funded by Jazz Pharmaceuticals. SAG has received consulting fees from Jazz Pharmaceuticals, and acknowledges data and writing support from Jazz Pharmaceuticals.
Comment on
-
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome.Lancet Haematol. 2023 Jul;10(7):e487-e488. doi: 10.1016/S2352-3026(23)00161-8. Lancet Haematol. 2023. PMID: 37407138 No abstract available.
-
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome.Lancet Haematol. 2023 Jul;10(7):e487. doi: 10.1016/S2352-3026(23)00162-X. Lancet Haematol. 2023. PMID: 37407139 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
